Amie C. O’Donoghue, Ph.D., is a Social Science Analyst in the Division of Drug Marketing, Advertising, and Communications (DDMAC), Center for Drug Evaluation and Research (CDER), Food and Drug Administration. As such, she conducts research on direct-to-consumer (DTC) advertising and the communication of information to physicians and consumers. She also provides technical assistance on research and communication issues to DDMAC staff, CDER staff, and external groups and organizations. Before joining DDMAC, Dr. O’Donoghue taught psychology at St. Mary’s College of Maryland. She received her doctorate in psychology from Washington University in St. Louis and her undergraduate degrees in psychology and studio art from Lafayette College.

Arnold I. Friede is counsel to the law firm of McDermott Will & Emery LLP based in its Washington, D.C. office. Arnie is a member of the Firm’s Health Law Department. Arnold I. Friede is a widely respected food and drug law counselor and advocate with significant advertising law, health care law, First Amendment, environmental, and commercial and transactional experience. He has a long history of direct involvement in successfully representing clients in FDA-regulated matters beginning as an Associate Chief Counsel in the FDA Chief Counsel’s Office, as well as a broad spectrum of senior in-house legal experience across multiple FDA-regulated industries.

Arnie has had a distinguished career of highly responsible, diverse, and complex positions. He served in government as a law clerk in Federal District Court in Los Angeles, and then with the Federal Judicial Panel on Multidistrict Litigation in Washington, DC, and as an Associate Chief Counsel in the FDA Chief Counsel's Office in Rockville, Maryland. Afterwards with Richardson-Vicks in Wilton, Connecticut, and then with several divisions of Unilever United States, including as General Counsel of Unilever’s U .S. food business in New Jersey, and then as senior corporate counsel with Pfizer in New York, Mr. Friede has been involved for nearly 35 years in a broad range of FDA and other agency-regulated businesses, including the life sciences, such as pharmaceutical and biotech, medical device, medical information, disease management, and over-the-counter drugs, as well as in the food, cosmetic, chemical and other industries. He has a breadth and depth of experience across an array of substantive legal areas and business operations.

Mr. Friede received his B.S. degree in Mathematics from the University of Pittsburgh and his J.D. from the George Washington University School of Law. In addition to numerous other professional affiliations, he is a past-Chairman of the Food, Drug, and Cosmetic Law Section of the New York State Bar Association.
Arnie is a frequent speaker and author on a wide range of topics of interest to the pharmaceutical, biotech, medical device, and life science industries generally.

Mr. Friede is admitted to practice in California, Connecticut, the District of Columbia, and Maryland

Aziz Mottiwala leads Consumer Promotion across Allergan's Dry Eye product franchise, which includes the Refresh line of over the counter artificial tears and Allergan's flagship prescription Eyecare brand, Restasis. His management of the Dry Eye DTC and CRM strategies has contributed tremendously to the growth of Restasis, which is on track to becoming the #1 prescribed pharmaceutical in all of Eyecare.

Aziz has more than 10 years of experience in the pharmaceutical industry, spanning a broad range of commercial responsibilities in numerous therapeutic areas. His expertise has contributed to strategies for both in-line and development products, as well as licensing and acquisition projects. He is known for is expertise in marketing analytics and research and is able to apply his experience to provide a keen perspective on brand strategy development.

Prior to joining Allergan, Aziz worked for Valeant Pharmaceuticals where his responsibilities included product management, business development, and marketing analytics. While at Valeant he managed the Hepatitis C and Parkinson’s disease franchises, as well as one of Valeant’s largest business development acquisitions.

Aziz began his career in pharmaceuticals at Aventis (now Sanofi-Aventis), in sales, with steadily increasing responsibilities in sales training and sales management. He holds a BS in Biochemistry from UC San Diego, and an MBA from the Marshall School of Business at the University of Southern California

Bill Novelli is CEO of AARP, a membership organization of over 40 million people age 50 and older, half of whom remain actively employed. AARP’s mission is to enhance the quality of life for all as we age.
Prior to joining AARP, Mr. Novelli was President of the Campaign for Tobacco-Free Kids, whose mandate is to change public policies and the social environment, limit tobacco companies’ marketing and sales practices to children and serve as a counterforce to the tobacco industry and its special interests. He now serves as chairman of the board.

Previously, he was Executive Vice President of CARE, the world’s largest private relief and development organization. He was responsible for all operations in the U.S. and abroad. CARE helps impoverished people in Africa, Asia and Latin America through programs in health, agriculture, environmental protection and small business support. CARE also provides emergency relief to people in need.

Earlier, Mr. Novelli co-founded and was President of Porter Novelli, now one of the world’s largest public relations agencies and part of the Omnicom Group, an international marketing communications corporation. He directed numerous corporate accounts as well as the management and development of the firm. Porter Novelli was founded to apply marketing to social and health issues, and grew into an international marketing/public relations agency with corporate, not-for-profit and government clients. He retired from the firm in 1990 to pursue a second career in public service. He was named one of the 100 most influential public relations professionals of the 20th century by the industry’s leading publication.

Mr. Novelli is a recognized leader in social marketing and social change, and has managed programs in cancer control, diet and nutrition, cardiovascular health, reproductive health, infant survival, pay increases for educators, charitable giving and other programs in the U.S. and the developing world.

He began his career at Unilever, a worldwide-packaged goods marketing company, moved to a major ad agency, and then served as Director of Advertising and Creative Services for the Peace Corps. In this role, Mr. Novelli helped direct recruitment efforts for the Peace Corps, VISTA, and social involvement programs for older Americans.

He holds a B.A. from the University of Pennsylvania and an M.A. from Penn’s Annenberg School for Communication, and pursued doctoral studies at New York University. He taught marketing management for 10 years in the University of Maryland’s M.B.A. program and also taught health communications there. He has lectured at many other institutions. He has written numerous articles and chapters on marketing management, marketing communications, and social marketing in journals, periodicals and textbooks.

His book, 50+: Give Meaning and Purpose to the Best Time of Your Life, was updated in 2008.

Mr. Novelli serves on a number of boards and advisory committees. He and his wife, Fran, reside in Bethesda, Maryland. They have three adult children and five grandchildren.

Christopher M. Schroeder is Chief Executive Officer of HealthCentral (www.healthcentral.com), a the highest quality collection of condition and wellness-specific interactive experiences focused on people finding and sharing real-life experiences related to their health needs. HealthCentral also manages the leading condition-specific health online advertising network. The Company has partnerships with leading online health tools (such as Microsoft’s HealthVault) and with over 25 leading health non-profits (such as The American Diabetes Association). HealthCentral’s sites reach over 10 million unique users each month. Backed by Polaris Ventures, Sequoia Capital, The Carlyle Group and Allen & Co., HealthCentral recently signed a significant strategic partnership with Interactive Corp (IAC) raising considerable capital for investments and acquisitions. IAC CEO Barry Diller serves on the company’s Board of Directors.

A veteran of online media, Schroeder served as CEO and Publisher of Washingtonpost.Newsweek Interactive, which hosts washingtonpost.com and newsweek.msnbc.com, among other leading news and information web sites. During his tenure, the Company more than quadrupled in revenue and audience, and reached profitability. Previously, Schroeder was CEO and President of LEGI-SLATE, INC, a leading online provider of information on federal and state legislation and regulation for businesses, law firms, government and other organizations. After implementing significant reorganization and operational improvements, Schroeder successfully negotiated the sale of LEGI-SLATE in 1999.

Prior to joining The Washington Post, Schroeder was a partner with Thayer Capital Partners, a leading private equity company in Washington, DC, and with the investment bank Salomon Brothers in New York, focusing on corporate finance and mergers and acquisitions projects for a wide range of Fortune 500 companies. Schroeder has also had extensive government experience, serving in leading management roles in President George Bush’s 1988 and 1992 election campaigns, and working on Secretary of State James A. Baker’s staff with then Under Secretary (and currently President of the World Bank) Robert Zoellick.

Schroeder is a leader in the interactive advertising and marketing services industry. He was a co-founder, and served as Chairman, of the Online Publishers Association (OPA), a leading research and information organization comprised of the CEOs of top online quality content publishers (including MSNBC, The NY Times, Dow Jones, ESPN.) He has served on the Board of the Interactive Advertising Bureau (IAB). He has been an investor in and advised companies including the leading high quality hotel booking site, www.fivestaralliance.com, the top career navigation network www.gottamentor.com, and the premier sports blogging company www.sbnation.com. He also has been active in the successful seed investment group, www.launchboxdigital.com.

He has won numerous awards, including 2008 PharmaVOICE Top 100 Most Inspiring People in Life Sciences, was one of the first interactive executives named to the American Advertising (AAF) Hall of Achievement (a national annual award honoring the leading executives in advertising under the age of 40), and The Silver Medal Award from the AAF and Advertising Club of Metropolitan Washington. Schroeder was named one of the top 40 business executives to watch by Business Forward Magazine, and named among the top 50 most influential people in online media and interactive advertising by Media Magazine.

Schroeder is a member of The Council on Foreign Relations, serves on the board of the National Cathedral elementary school, and is active in several non-profits. He graduated magna cum laude from Harvard College and with honors from Harvard Business School. He is married to Alexandra Coburn, and has three children: Jack 12, Julia 10 and Ben 7.

Dr. Michal Galin leads Starch Communications, which specializes in measuring ad effectiveness. As such she has a wealth of information about how marketers can entice people to see and respond to their advertising. Mickey also serves as SVP, Research for MRI’s syndicated national readership study, The Survey of the American Consumer, as well as MediaDay and the Issue Specific Readership Study.

Dr. Galin joined Mediamark in 2001 shortly after receiving her doctorate from Cornell University. She is a member of the Advertising Research Foundation (ARF) Print Council, the ARF Online Quality Council, the Market Research Council and AAPOR. Dr. Galin has presented papers at the ESOMAR Worldwide Audience Measurement Conference, the ARF Print-Electronic Meeting, the Worldwide Readership Symposium, the American Evaluation Association Annual Conference, the AAPOR Annual Conference, and at the European Association on Research, Learning and Instruction Conference.

With more than 16 years experience, Fariba is a seasoned advertising research expert, well known for her work and public speaking on the impact of prescription drug advertising on consumer response since its inception in the late 90’s.

Fariba joined IAG Research in 2005 charged with the development of the healthcare practice. There she currently leads the team in product development; marketing and client management for IAG’s syndicated television ad performance measurement tools including program engagement. Her tenure with DTC advertising has been instrumental to the company’s significant growth within this sector specifically, identifying synergies that exist between the creative and the selected TV media to enhance campaign ROI. IAG is currently in the process of being acquired with The Nielsen Company where Fariba will be retained to expand the breadth of products and advertising and media services provided within the healthcare space, specifically measurement of alternative promotion channels such as internet and mobile web on DTC advertising.

Before joining IAG, Fariba was a resident consumer behavior expert at Ipsos-Insight where she was Vice President of marketing and business development of Ipsos Health; a practice dedicated to providing custom and syndicated research to prescription drug. Here is where she began her specialization in monitoring consumer response to direct-to-consumer advertising for prescription drugs. She was the founder of Ipsos PharmTrends®, a syndicated consumer tracking tool that measured consumer behavioral response to DTC initiatives across ailment categories, which first began tracking the pioneering efforts of the Claritin marketing team.

Through her development and management of these various performance tracking tools, Fariba is a recognized opinion leader and contributor to industry journals, conferences, and events. Before focusing on the pharmaceutical industry, Fariba specialized in retail and consumer research for the consumer products industry, including consumer packaged goods, apparel, and athletic footwear, as well as primary research and tracking expertise within the music and entertainment sectors. Fariba has a Bachelor of Science in Marketing and International Business from Ithaca College.

Jean-Luc Pilon Senior Director, Consumer Marketing, Sanofi-Aventis

Mr. Pilon has over 25 years of marketing and sales experience with successful positions in leading packaged goods and pharmaceutical companies.

In October 2005, Mr. Pilon led the consumer launch of Ambien CR, a dual action formula of Ambien, the most popular sleep aid in the US. Ambien CR competes in one of the fastest growing and most competitive therapy area.

Prior to joining sanofi-aventis, Mr. Pilon led the worldwide professional marketing efforts of Oral-B at Gillette. He launched Pulsar, the first pulsing toothbrush and Triumph, the most advanced rotating power toothbrush.

From 1989 to 2003, Mr. Pilon held different marketing and sales positions at GSK in Canada and in the US. He spearheaded the DTC Center of Excellence for the pharma division, led Zyban, the first non-nicotine replacement therapy as well as the pre-launch of Avodart, a BPH drug that reduces enlarged prostates. He managed in collaboration with Warner Lambert (joint venture), the destiny of the Rx-to-OTC switches of Zovirax Cold Sore Cream and Beconase Allergy. In Canada, he led, at different points in time, the marketing effort of Sudafed, Actifed, Zincofax and Nix as well as the OTC sales force in the province of Quebec.

Before joining GSK, Mr. Pilon worked for the pet food division (Puss n’ Boots, Flavour Morsels, Pamper, Pounce) of Quaker Oats Canada and for the snack food division (Vachon) of Culinar, a Canadian food conglomerate. He started his career as a client representative/analyst at A.C. Nielsen Canada.

Mr. Pilon holds a Bachelor of Commerce from McGill University.

For two decades, Jim Davidson has helped companies and business associations define and achieve their goals in the legislative and regulatory arenas of the federal government. He is founder of Davidson & Company, a public policy advisory firm,which is a subsidiary of Polsinelli Shalton Welte Suelthaus.

Davidson & Company has helped its clients address a broad range of public policy areas including advertising regulation and commercial speech, appropriations, taxation, healthcare, telecommunications and the Internet. Through his work on behalf of The Advertising Coalition, Mr. Davidson has become widely known as an expert on advertising regulation and specifically on prescription drug advertising. He also was asked by leaders in the advertising and food manufacturing industries to help make Congress and the American public more aware of industry initiatives to introduce new products and promote healthy lifestyles. He writes the “Eye on Washington” column on prescription drug advertising for DTC Perspectives Magazine, and a column on federal government issues for Electronic Retailer Magazine.

Mr. Davidson served as Chief Counsel and Staff Director for the Senate Judiciary Subcommittee on Administrative Practice and Procedure. In that capacity, he directed the drafting of omnibus regulatory reform legislation and the Regulatory Flexibility Act. He also was Chief Counsel of the Governmental Affairs Subcommittee on Intergovernmental Relations where he was a principal staff author of the federal Privacy Act and major amendments to the Freedom of Information Act.

While serving on the Intergovernmental Relations Subcommittee, Mr. Davidson was
singled out for recognition in the book Unelected Representatives: Congressional Staff and the Future of Representative Government. Prior to that, he served as Special Assistant and Press Secretary to Missouri Senator Stuart Symington, and as Administrative Assistant to Missouri Secretary of State James C. Kirkpatrick.

Mr. Davidson is a graduate of the University of Missouri-Columbia Schools of Journalism and Law, and served as an adjunct Professor of Law at the Washington College of Law at American University. He is a member of the District of Columbia Bar, the Missouri Bar Association, and the American Bar Association. He was a Fellow of the American Council on Germany, and was a Conferee at the Chief Justice Earl Warren Conferenceon Advocacy.

John has expertise in the development and application of models for commercial optimization decisions. He has served pharmaceutical clients across a broad range of therapeutic areas. He joined IMS in 2002 as a manager in statistical services where he developed statistical and optimization models. During that time he developed many new innovations including patient-level modeling to better understand how promotions impact patient behavior; and physician-level modeling to identify and target those physicians who have been responsive to detailing and sampling.
 
Before joining IMS HEALTH, John served as a consultant in the marketing research practice of ZS Associates. He conducted primary research for clients for segmentation and ATU studies. In addition, John served as AVP, Marketing Analytics with global ad shop, Euro RSCG. While at Euro he spearheaded efforts to develop methods that optimize both “below the line” and “above the line” promotions across industries.
 
John has presented research at industry conferences including:
-DTC National Conference, 2008 on the ROI of the Top 25 DTC spenders
-DTC National Conference, 2006 on the impact of unbranded DTC
-Pharmaceutical Management Science Association (PMSA) Conference, 2004 on physician level modelling and targeting strategies
-American Marketing Association Advanced Research Techniques Forum (poster), 2004 on physician level modelling using hierarchical Bayesian methods.
 
John graduated from the Olin School of Business, Washington University in St. Louis with a Master of Business Administration in 2001 and from Appalachian State University with a Bachelor of Science in Business Administration in 1994.

Best-selling author and pioneer of account planning in American advertising agencies, John has designed brand strategies for clients for almost twenty-five years, guiding campaigns to international strategic and creative acclaim. His new book, The Brand Bubble: The Looming Crisis in Brand Value and How To Avoid It was voted #3 Best Business Book for 2008 from Amazon’s editors and ‘Best Advertising and Marketing Book for 2008’ from CEO Read. And the book is currently on Business Week’s Best Seller List. A sought after presenter around the world,Gerzema previously oversaw the international network for Fallon and founded offices in Tokyo, Singapore, Hong Kong and Sao Paolo. He holds a master’s degree in integrated marketing from the Medill School of Journalism at Northwestern University and a B.S. in marketing from Ohio State University.

John F. Kamp is the Executive Director of the Coalition for Healthcare Communication, a drug-marketing group with offices in NYC and Washington, DC. He is also of counsel with the law firm Wiley Rein & Fielding, LLP, and well known and often quoted advocate for First Amendment rights of individuals and corporations.

His professional experience includes 10 years with the DC office of the American Association of Advertising Agencies and nearly a decade in public policy positions at the Federal Communications Commission (FCC). Before moving to Washington, Kamp taught journalism at the University of Iowa and Tulsa University. Dr. Kamp earned a bachelor’s degree at the University of Notre Dame, a doctorate from the University of Iowa School of Journalism, and a juris doctorate at the University of Tulsa School of Law.

Numerous medical executives prize Dr. Kamp’s public policy expertise, and he is a frequent speaker at industry meetings on the legal and political issues surrounding drug marketing. He serves on the public advisory committees of the American Academy of Family Physicians and WebMD. He is an editorial advisor for the Rx Compliance Report and the FDA Advertising and Promotion Manual, and co-author with Wayne Pines of a book from FDA News on compliance with FDA drug policy.

Marci Hanlon Director Orencia Consumer Marketing, Bristol-Myers Squibb

Marci Hanlon has over 18 years experience in healthcare and consumer sales and marketing. Prior to Bristol-Myers Squibb she worked for Bayer in their Consumer, Biological, and Pharmaceutical businesses. Marci held several roles of increasing responsibility including Regional Sales Manager before entering marketing. Marci held several positions within marketing for Bayer, including strategic marketing, e-business/CRM, and product management roles which included working on the DTC launch of Levitra. At Bristol Myers, Marci and her team are responsible for all advertising, media, public relations, direct marketing and database marketing, internet, sponsorships and consumer efforts for the brand ORENCIA.

Marci C. Kiester, Pharm.D. is the Leader, Direct-to Consumer Review Group II, Division of Drug Marketing, Advertising, and Communications (DDMAC), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA). Dr. Kiester joined DDMAC in 2001 as a Senior Regulatory Review Officer and was responsible for the review of products in the Gastrointestinal, Anticoagulant, and Diabetes therapeutic classes. In 2003, Dr. Kiester became the Leader for Professional Review Group IV. In November 2006, she transitioned to her current role as Leader of Direct-to-Consumer Review Group II.

Prior to joining DDMAC, Dr. Kiester worked with AdvancePCS (currently CareMark) as a Clinical Program Director. She received her Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from Duquesne University. Dr. Kiester also completed a residency in Managed Care Pharmacy with AdvancePCS/University of Maryland.

Mark Senak is an attorney with over twenty years of experience offering a blend of law, communications, public health and public relations. His experience as a lawyer, his background in public health and his knowledge of communications and public affairs have made him an ideal counselor and strategist for clients needing regulatory communications counsel, litigation, crisis and issues management.

Mr. Senak has designed communications campaigns and built coalition grassroots support efforts targeting public health and health policy issues at state, federal and global levels. Mr. Senak’s expertise has been put to work in two primary areas as they are related to health policy – public health and medical product development, with an emphasis on regulatory approval and reimbursement strategies.

As a trend-spotter, Mr. Senak is the author of the Web Log (blog) ‘Eye on FDA’ (www.eyeonfda.com/) which is a professional blog that breaks through medical-legal jargon and provides patients, healthcare providers, journalists, analysts and members of the pharmaceutical industry as well as regulators themselves with a one-stop-shop of industry analysis. The site aims to help all healthcare industry stakeholders understand the US regulatory environment and its impact on the marketplace, and is increasingly providing an authoritative voice on how it compares to markets outside of the US, including the UK and Europe. The blog has been regularly ranked by edrugsearch.com as one of the top 100 blogs on health and medicine. He also authors a monthly column called FDA Watch in the peer reviewed journal – American Health & Drug Benefits.

His medical product crises and issues management work has included a broad range of issues of such as pricing, company boycotts, clinical trial issues (adverse events and withdrawal of trials), serious adverse event communication, compulsory licensing issues and product labeling as well as litigation matters and adulterated food products. His work has led to extensive experience in several therapeutic areas, including diabetes, HIV/AIDS, osteoporosis and various aspects of women’s health, allergy/asthma, oncology and gastroenterology as well as consumer and public health work in HIV/AIDS.

Mr. Senak received his Bachelor of Arts degree from the University of Illinois and his law degree from Brooklyn Law School. He is the author of several magazine and newspaper articles as well as three books examining issues of law, health policy and HIV as well as the rights of the gay, lesbian, bisexual and transgendered community.

Melissa Clark Director, Integrated Consumer Marketing, CV Franchise, Novartis

Melissa Clark is the the director, integrated consumer marketing at Novartis Pharmaceuticals for thecardiovascular/metabolic franchise. She is responsible for ensuring overall strategic alignment and driving integration across all key consumer functions to optimize effectiveness and efficiencies within the franchise for hypertension medications. In this position, she has led the development of the first CVM franchise consumer marketing strategic and tactical plan and is now leading an effort to ensure executional excellence and evaluation of all key cross-franchise consumer initiatives.

Clark previously was part of the Novartis CVM innovations team, where she successfully led the development and implementation of the CV franchise relationship marketing program The BP Success Zone (BPSZ) for Diovan, Diovan HCT and Lotrel. In addition, she led several cross-franchise consumer initiatives, including the integration of the recently launched Tekturna and Exforge Brands into the BPSZ Program. The BPSZ Program received the First Place Best Relationship Marketing PhAME Award in 2007, as well as the Gold In-Awe Award in 2006.

Previously at Novartis, she was Associate Director of Marketing on the Diovan Brand Team where she led the Consumer DTC/DTP strategic and tactical plan development and execution, including the consumer campaign launch of the Take Action for Healthy BP Program. Melissa played an instrumental role in driving the creative strategy and execution of all major elements for the consumer campaign including TV, Print and in-office materials.

Clark earlier held marketing positions at Pharmacia/Pfizer, where she was an associate director of consumer marketing. Her responsibilities included driving the DTC/DTP launch for the COX-2 inhibitor Bextra, leading the DTC/DTP efforts for the women’s health portfolio that included new product launches for Activella, Lunelle and Vagifem, and new consumer initiatives on Depo-Provera. She also successfully led the company’s first unbranded and branded DTC efforts for the launch of Detrol for OAB.

Prior to her pharma experience, Clark spent more than six years in brand management positions in consumer-packaged goods at Nabisco Foods Inc.’s Specialty Products Division and in consumer advertising working on large consumer brands at Trone Advertising Inc.

She earned a B.A. degree in advertising/communications at The University of North Carolina-Chapel Hill in 1990 and her MBA from Wake Forest University’s Babcock School of Management in 1995.

As Vice President of Research for Manhattan Research,Meredith Abreu Ressi specializes in consumer and physician-Health trends and strategy.

Prior to her work with ManhattanResearch, Mrs.Ressiwas the COO of Integrated Wellness Solutions, overseeing development and deployment of software, content, and programs designed to provide behavior-based online health interventions for disease management, pharmaceutical compliance and corporate wellness initiatives.

Mrs.Ressi also worked asVice President o fBusiness Development for Nutricise.com,
where she was responsible for product development, marketing and outcomes optimization for the company's consumer portal, aswell as its B2B content licensing and private label web development partnerships.

Prior to herworkwithNutricise, Mrs.Ressi was a Research Associate specializing in mergers and acquisitions with Economists Incorporated, an economic consulting firm in Washington,DC.

Mrs.Ressi received her BA in Economics from Brown University.

Michael McCaughan is Editor-in-Chief of FDC-Windhover’s Biopharma Group, the leading publisher of news and information services for the pharmaceutical industry, including The Pink Sheet, IN VIVO, The RPM Report, PharmAsia News, and The IN VIVO Blog. McCaughan speaks frequently on regulatory and policy developments affecting the biopharmaceutical industry.

McCaughan joined "The Pink Sheet" in 1990 as a business reporter. He became Assistant Managing Editor in 1993, Managing Editor in 1995 and Editor-In-Chief in 1996. He oversees an editorial staff of 35, and helped launch affiliated publications and on-line services, including Pharmaceutical Approvals Monthly, FDAAdvisoryCommittee.com, “The Pink Sheet” On The Web, “The Pink Sheet” DAILY and The RPM Report. McCaughan is a summa cum laude graduate of Yale University.

Paula Garrett Director,Consumer Marketing Eli Lilly & Co

Paula Garrett oversees all consumer marketing and advertising efforts for Cialis, and is responsible for leading the company’s largest efforts ever in the direct-to-consumer marketplace.

She began her career at Procter & Gamble, working on Puffs, Charmin, White Cloud and new tissue products. She also was one of the first brand marketers selected to work on the Wal-Mart customer team, an initiative that changed the way packaged-goods companies work with their leading retail partners.

Following her stint at P&G, Garrett worked for Coca-Cola, overseeing promotional strategies in the fountain division. She moved to Johnston & Murphy, the high-end footwear company, where she was responsible for developing the strategic blueprint for the brand’s first two line extensions. Garrett later applied her brand strategy and marketing experience to a four-year consulting role for companies such as Kraft, Dockers Footwear and the PGA Tour.

Garrett graduated from Southern Methodist University with a BA in political science and a BFA in journalism, and earned her MBA at Indiana University. She lives in Indianapolis with her husband, David, and enjoys playing golf, traveling and reading.

Bob has spent the majority of his life doing the heavy lifting...literally and figuratively. As a heavy-duty power lifter, he raised weights and eyebrows. As a marketing executive, he has spent his entire career building brands and businesses, creating competitive organizations that thrive on challenges as well as lifting revenue and profits. He is an inspired problem-solver, constantly in pursuit of new ideas…that are bigger, better, faster, stronger. Having spent 30 years on both the client and service side of the business plan, Bob holds a unique understanding of the issues facing organizations and their brands. He understands and appreciates what his clients go through, because he’s been in their shoes……….

After rising to senior sales and marketing positions in the Consumer and HBA industries at Nabisco Brands and Colgate Palmolive, Bob worked as a marketing ‘turnaround specialist’ for a global investment company, where he was responsible for breathing new life into consumer marketing organizations.…including a Germany-based wine company where he served as CEO and helped capitalize and launch a unique wine-producing technology.

In 1996, Bob became a Principal at The Gramercy Group, an integrated marketing communications firm (acquired by Publicis North America in 1999) that focused on the healthcare and pharmaceutical industries. It was here he became an early pioneer in DTC marketing, applying years of integrated marketing experience to this new field. Bob recognized the importance for nedd of an integrated DTC/CRM continuum and spearheaded the Agency’s initial DTC efforts for Eli Lilly & Company into the Diabetes and Women’s Healthcare arenas.

For the last 12 years, Bob has continued to leverage his expertise in branding, audience segmentation, positioning, advertising, compliance, and promotion across a variety of fields including diabetes/insulin recombinant technology, mental health, eye care, osteoporosis, pain management, obesity, metabolic syndrome and medical diagnostics/devices.

Bob leads the DTC and Strategic Groups at Beacon Healthcare, currently focusing on assisting the Allergan Consumer ophthalmic team’s efforts in business planning, DTC/CRM marketing, and patient compliance….

He holds undergraduate and graduate degrees from Syracuse and Colgate Universities.

Mr. Trujillo is Director of U.S. Consumer for Women’s Healthcare products with a focus on fertility control products. In this role, he is responsible for the full scope of direct to consumer marketing including: television, print, digital, entertainment marketing and the development of promotional materials for healthcare professionals. Key product responsibilities include consumer promotions for, YAZ “Best Oral Contraceptive Launch” (MedAd News) “Second Best Product launch 2006 – 2008”, Mirena “Fastest Growing” Intra Uterine Contraceptive/first on television and Angeliq (hormone therapy) launch. Sam has over 25 years experience consumer and pharmaceutical marketing, department leadership, strategic planning, new product commercialization, life cycle management, field sales management Fortune 100 companies such as Procter & Gamble, Warner-Lambert and Bayer Healthcare, start-up companies such as Shire and marketing internship at The Walt Disney Company. Track record of success serving on, or leading, teams for many well-known brands, with over a dozen product launches, four of which have reached blockbuster status. Experience leading pharmaceutical and consumer product marketing teams, globally and in US, across several therapeutic categories Education includes: Biochemistry - University of New Mexico, Business/Marketing - Michigan Business School, Law/Business - Pepperdine University

From 2002 through 2004, Mr. Moloney was a director on the Marketing Innovation team at Pfizer, Inc., the world's largest pharmaceutical company. He was responsible for the development of Pfizer's online medical marketing and education research and executed award-winning campaigns that leveraged multimedia, video and interactive case-based learning environments, with emphasis on the cardiovascular opportunity. Sean's contributions were recognized under the Steere Quota Achievers Leadership Award program at Pfizer in 2004.